Acadia Pharmaceuticals Inc (ACAD) stock
ACADNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 17/3041% below fair value
$18.75+0.61 (+3.36%)
Close on Nov 13, 2026Market cap $3.23BP/E 8.9Yield –
Acadia Pharmaceuticals gross margin
Gross margin is gross profit as a percentage of revenue.
Acadia Pharmaceuticals's gross margin for the twelve months ending Sep 30, 2026 was 90.5%. For fiscal 2025 it was 91.7%, against 91.5% the year before. The highest annual figure on record is 98.0% in fiscal 2022.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 91.7% | +0.2 |
| FY2024 | Dec 31, 2024 | 91.5% | −2.8 |
| FY2023 | Dec 31, 2023 | 94.3% | −3.8 |
| FY2022 | Dec 31, 2022 | 98.0% | +0.3 |
| FY2021 | Dec 31, 2021 | 97.8% | +0.1 |
| FY2020 | Dec 31, 2020 | 97.7% | +1.0 |
| FY2019 | Dec 31, 2019 | 96.7% | +2.2 |
| FY2018 | Dec 31, 2018 | 94.5% | +1.7 |
| FY2017 | Dec 31, 2017 | 92.7% | +10.5 |
| FY2016 | Dec 31, 2016 | 82.2% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 89.7% | −2.5 |
| Q2 FY2026 | Jun 30, 2026 | 90.8% | −1.4 |
| Q1 FY2026 | Mar 31, 2026 | 90.8% | −0.9 |
| Q4 FY2025 | Dec 31, 2025 | 90.8% | −0.8 |
| Q3 FY2025 | Sep 30, 2025 | 92.2% | −0.2 |
| Q2 FY2025 | Jun 30, 2025 | 92.2% | −0.3 |
| Q1 FY2025 | Mar 31, 2025 | 91.7% | +2.8 |
| Q4 FY2024 | Dec 31, 2024 | 91.6% | −0.7 |
| Q3 FY2024 | Sep 30, 2024 | 92.5% | −0.6 |
| Q2 FY2024 | Jun 30, 2024 | 92.5% | −3.0 |
| Q1 FY2024 | Mar 31, 2024 | 88.8% | −9.7 |
| Q4 FY2023 | Dec 31, 2023 | 92.3% | −6.0 |
| Q3 FY2023 | Sep 30, 2023 | 93.1% | −5.3 |
| Q2 FY2023 | Jun 30, 2023 | 95.5% | −2.5 |
| Q1 FY2023 | Mar 31, 2023 | 98.6% | +1.1 |
| Q4 FY2022 | Dec 31, 2022 | 98.2% | +0.1 |
| Q3 FY2022 | Sep 30, 2022 | 98.4% | +1.2 |
| Q2 FY2022 | Jun 30, 2022 | 98.0% | +0.2 |
| Q1 FY2022 | Mar 31, 2022 | 97.4% | −0.5 |
| Q4 FY2021 | Dec 31, 2021 | 98.1% | +0.2 |
| Q3 FY2021 | Sep 30, 2021 | 97.2% | −1.1 |
| Q2 FY2021 | Jun 30, 2021 | 97.8% | +0.4 |
| Q1 FY2021 | Mar 31, 2021 | 97.9% | +1.1 |
| Q4 FY2020 | Dec 31, 2020 | 97.9% | +1.0 |
| Q3 FY2020 | Sep 30, 2020 | 98.3% | +0.9 |
| Q2 FY2020 | Jun 30, 2020 | 97.4% | +0.9 |
| Q1 FY2020 | Mar 31, 2020 | 96.9% | +1.6 |
| Q4 FY2019 | Dec 31, 2019 | 96.9% | +1.7 |
| Q3 FY2019 | Sep 30, 2019 | 97.4% | +4.0 |
| Q2 FY2019 | Jun 30, 2019 | 96.4% | +2.7 |
| Q1 FY2019 | Mar 31, 2019 | 95.3% | −0.3 |
| Q4 FY2018 | Dec 31, 2018 | 95.3% | +0.9 |
| Q3 FY2018 | Sep 30, 2018 | 93.4% | −0.6 |
| Q2 FY2018 | Jun 30, 2018 | 93.8% | +1.1 |
| Q1 FY2018 | Mar 31, 2018 | 95.6% | +10.4 |
| Q4 FY2017 | Dec 31, 2017 | 94.4% | +8.6 |
| Q3 FY2017 | Sep 30, 2017 | 94.0% | – |
| Q2 FY2017 | Jun 30, 2017 | 92.7% | – |
| Q1 FY2017 | Mar 31, 2017 | 85.2% | – |
| Q4 FY2016 | Dec 31, 2016 | 85.8% | – |
See a number that looks wrong?